Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;148(6):853-9.
doi: 10.1038/sj.bjp.0706792. Epub 2006 Jun 12.

NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy

Affiliations

NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy

Philipp Kalk et al. Br J Pharmacol. 2006 Jul.

Abstract

1. Chronic renal disease is associated with oxidative stress, reduced nitric oxide (NO) availability and soluble guanylate cyclase (sGC) dysfunction. Recently, we discovered BAY 58-2667, a compound activating heme-deficient or oxidized sGC in a NO-independent manner. 2. We assessed potential of BAY 58-2667 in preventing cardiac and renal target organ damage in rats with 5/6 nephrectomy. 3. Male Wistar rats were allocated to three groups: 5/6 nephrectomy, 5/6 nephrectomy treated with BAY 58-2667 and sham operation. Study period was 18 weeks: blood pressure and creatinine clearance were assessed repeatedly. At study end blood samples were taken and hearts and kidneys harvested for histological studies. 4. BAY 58-2667 markedly lowered blood pressure in animals with 5/6 nephrectomy (untreated versus treated animals: 189+/-14 versus 146+/-11 mmHg, P<0.001). Left ventricular weight, cardiac myocyte diameter as well as cardiac arterial wall thickness significantly decreased in comparison to untreated animals with 5/6 nephrectomy. Natriuretic peptide plasma levels were also improved by BAY 58-2667. Kidney function and morphology as assessed by creatinine clearance, glomerulosclerosis, interstitial and perivascular fibrosis of intrarenal arteries were likewise significantly improved by BAY 58-2667. 5. This is the first study showing that BAY 58-2667 effectively lowers blood pressure, reduces left ventricular hypertrophy and slows renal disease progression in rats with 5/6 nephrectomy by targeting mainly oxidized sGC. Therefore, BAY 58-2667 represents a novel pharmacological principle with potential clinical value in treatment of chronic renal disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Creatinine clearance. All values are given as mean±s.d. **P<0.001 versus sham OP. P<0.05 versus 5/6 NX.
Figure 2
Figure 2
Systolic blood pressure. All values are given as mean±s.d.. **P<0.001 versus sham OP. P<0.001 versus 5/6 NX.
Figure 3
Figure 3
Relative left cardiac ventricle weight. All values are given as mean±s.d.. *P<0.05 versus sham OP. P<0.05 versus 5/6 NX.
Figure 4
Figure 4
Typical sections of heart and kidney. (a) 5/6 NX; (b) 5/6 NX+BAY 58-2667; (c) sham OP. First column: typical cardiac arteries in Elastica-van Gieson staining, Magnitude × 200. Second column: typical kidney sections in PAS staining, Magnitude × 200. Presence of PAS-positive material (pink color) within glomeruli indicates glomerulosclerosis. Third column: typical kidney sections in Sirius-Red-staining, Magnitude × 200. Red color indicates fibrotic areas.

References

    1. AMANN K., NEUSUSS R., RITZ E., IRZYNIEC T., WIEST G., MALL G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am. J. Hypertens. 1995;8:409–417. - PubMed
    1. ANGERMANN C.E., ERTL G. Natriuretic peptides – new diagnostic markers in heart disease. Herz. 2004;29:609–617. - PubMed
    1. BIDANI A.K., GRIFFIN K.A. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595–601. - PubMed
    1. DUMITRASCU R., WEISSMANN N., GHOFRANI H.A., DONY E., BEUERLEIN K., SCHMIDT H., STASCH J.P., GNOTH M.J., SEEGER W., GRIMMINGER F., SCHERMULY R.T. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286–295. - PubMed
    1. EL NAHAS M., BELLO A.K. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–340. - PubMed

Publication types